Bone Marrow & Stem Cell Transplant

In an interview, Brian C. Betts, MD, revealed how Roswell Park Comprehensive Cancer Center achieved a dramatic increase in patient survival after allogeneic hematopoietic cell transplant.

A randomized comparison of ATG, PTCy, and a combination helped characterize the similarities and differences of these regimens used as GVHD prophylaxis in stem cell transplant.

The T-cell immunotherapy Orca-T has gained FDA approval in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndromes (MDS).

A scoring tool combining frailty, chronological age, and comorbidities showed distinct outcomes among patients who received allogeneic hematopoietic cell transplant.

FBEM conditioning in ALL alloHSCT yielded 92.1% 2-year OS and 14.3% relapse rate, with 0% 100-day NRM and manageable GVHD in 203 patients.

Posttransplant revumenib maintenance in genetically defined AML shows promising survival and low relapse, with thrombocytopenia as key toxicity.

Heather Stefanski, MD, PhD, discusses the significance of reducing the dose of post-transplant cyclophosphamide in the OPTIMIZE trial.

In an interview, Rawan Faramand, MD, discussed her research on cost-effectiveness of graft modification to prevent GVHD in hematopoietic cell transplant.

Rawan Faramand, MD, discusses how reducing the cost of GVHD therapy could benefit health systems.

Gene editing donor cells enabled less toxic targeted maintenance posttransplant; study was not continued for fiscal reasons.

Rawan Faramand, MD, explains how a cost analysis supported Orca-T engineered graft by reducing the need for GVHD therapy vs standard prophylaxis.

Amandeep Salhotra, MD, discusses preclinical findings that could support the addition of a BCL2 inhibitor to address acute or chronic graft-vs-host disease.

A first-in-class allogeneic regulatory T-cell therapy advances into multicenter phase 1b/2a trial; trial start expected second half of 2026.

Jakafi XR offers bioequivalent alternative to twice-daily formulation; pharmacy availability expected by May 8.

In the ARES trial, MaaT013 led to improvement in refractory lower GI chronic GVHD, a key unmet need in patients receiving hematopoietic cell transplant.